Author: BusinessWire

Novel mucoadhesive patch adheres to wet tissue surfaces and enables targeted, localized delivery of therapeutic to lesions inside the mouth
SAN DIEGO & COPENHAGEN, Denmark–(BUSINESS WIRE)–AFYX Therapeutics (“AFYX”), a clinical stage biopharmaceutica…

DUBLIN–(BUSINESS WIRE)–The “Global Japanese Encephalitis Vaccines Market 2021-2025” report has been added to ResearchAndMarkets.com’s offering.

The publisher has been monitoring the Japanese encephalitis vaccines market and it is poised to grow by $…

DUBLIN–(BUSINESS WIRE)–The “Global Japanese Encephalitis Vaccines Market 2021-2025” report has been added to ResearchAndMarkets.com’s offering.

The publisher has been monitoring the Japanese encephalitis vaccines market and it is poised to grow by $…

DUBLIN–(BUSINESS WIRE)–The “Global Japanese Encephalitis Vaccines Market 2021-2025” report has been added to ResearchAndMarkets.com’s offering.

The publisher has been monitoring the Japanese encephalitis vaccines market and it is poised to grow by $…

– Webinar To Feature Therapeutic Expert Henry Kranzler, M.D. –
LEXINGTON, Mass.–(BUSINESS WIRE)–Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) th…

– Webinar To Feature Therapeutic Expert Henry Kranzler, M.D. –
LEXINGTON, Mass.–(BUSINESS WIRE)–Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) th…

DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glauco…

– Webinar To Feature Therapeutic Expert Henry Kranzler, M.D. –
LEXINGTON, Mass.–(BUSINESS WIRE)–Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) th…

– Webinar To Feature Therapeutic Expert Henry Kranzler, M.D. –
LEXINGTON, Mass.–(BUSINESS WIRE)–Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) th…

– Webinar To Feature Therapeutic Expert Henry Kranzler, M.D. –
LEXINGTON, Mass.–(BUSINESS WIRE)–Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) th…